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Abstract
CSF-1R is a receptor mostly associated with the mononuclear phagocytic system. However, its expression
within tumors has been linked with poor prognosis in both hum ans and dogs. Accordingly, several reports
have demonstrated the beneficial effects of blocking CSF-1R in model systems of cancer. In this study,
we generated a monoclonal antibody that could block CSF-1R i n dogs as the first step to develop an
anticancer drug for this species. Initially, an antibody wa s raised by the hybridoma methodology against
the fragment responsible for receptor dimerization. mAb3. 1, one of the resulting hybridoma clones, was
able to bind macrophages in fixed tissues and was shown to inhi bit cells of the mononuclear phagocytic
line. Nevertheless, mAb 3.1 could not bind to some glycoform s of the receptor in its native form, while also
demonstrating cross-reactivity with other proteins. To en hance binding properties of the mAb, five amino
acids of the complementarity-determining region 2 of the va riable heavy chain of mAb3.1 were mutated by
PCR, and the variant scFv clones were screened by phage displ ay. The selected scFv clones demonstrated
improved binding to the native receptor as well as increased anti-macrophage activity. The resulting
scFv antibody fragment presented here has the potential for use in cancer patients and in inflammatory
diseases. Furthermore, this work provides insights into th e use of such restricted mutations in antibody
engineering.
Statement of Significance:
• A mAb was created against canine CSF-1R by hybridoma; howeve r, it could not bind to some
glycoforms of CSF-1R;
• The Vh CDR 2 of the mAb was mutated, and the variant scFv clones were screened by phage display.
The restricted CDR 2-specific mutations increased antibody specificity.
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INTRODUCTION
CSF-1R expression and tumor-associated macrophages
(TAMs) are connected with poor prognosis in several
cancer types [1, 2]. The presence of TAMs is correlated with
increased proteinase expression, leading to tissue invasion
[3]. TAMs also assist cancer cells in penetrating blood
vessels [4]; they are linked to tumoral immunosuppression
and are associated with reduced responses to chemotherapy
[5]. Cancer cells recruit TAMs and establish a paracrine
loop of stimulation. In this interaction, the tumor secretes
CSF-1, which stimulates the macrophages, and in response
TAMs produce EGF, which induces cancer cell growth [6].
Because of its significance in the pathogenic progression of
cancer, CSF-1R has become an attractive target for drug
development.
Several antibodies have been raised against human and
murine CSF-1R [7–9] or against the CSF-1 [3]. Clinical
trials for breast and prostatic human cancer have been
conducted with an inhibitory anti-CSF-1R (https://www.cli
nicaltrials.gov/ct2/show/study/NCT02265536), and several
studies have been published analyzing the effects of anti-
CSF-1R mAbs in cancer models [10–13]. However, none
of the previously described antibodies targets the canine
receptor. Conversely, antibodies that were designed to iden-
tify canine macrophages through other receptors have been
raised, although none has been assessed for their ability to
block macrophage function or survival [14, 15].
As a clinical tool, antibodies that target the CSF-1R are
more suitable than antibodies that target its ligands, since
these have short circulation half-lives. Also, CSF-1R has
two ligands, CSF-1 and IL-34, which are structurally unre-
lated, therefore requiring different antibodies to block both
[16, 17]. Although both IL-34 and CSF-1 share a binding
site on the surface of CSF-1R, there are differences in the
receptor contact points for binding both ligands, which
overlap, but are not identical [16, 18]. Additionally, both of
these cytokines have dissimilar spatiotemporal expression
patterns, making the targeting of both difficult [19].
Two major strategies exist for blocking CSF-1R using
a mAb approach. The antibody can either inhibit ligand
binding to its receptor or it can inhibit receptor dimer-
ization. These effects can be performed by direct binding
of the antibody to the receptor regions responsible for
ligand recognition/dimerization or through stabilization of
a folded conformation of the receptor [20]. Stable dimer-
ization is essential for CSF-1R signaling [21]. Blocking
dimerization impedes signaling through both IL-34 and
CSF-1 and should fully stop CSF-1R signaling [16, 18].
The aim of this study was to identify an antibody that
could block the function of canine CSF-1R with the intent
of ultimately being able to use it to treat canine cancer
patients. For this, mAb 3.1 was generated against the dimer-
ization region of the receptor. Although it showed promis-
ing staining patterns in fixed tissue and demonstrated some
inhibitory activity against macrophages, it could only bind
to restricted glycoforms of the native CSF-1R. A small
library of semi-synthetic antibodies based on mAb 3.1 was
created by restricted mutations in the complementarity-
determining region 2 (CDR2) from the antibody variable
heavy chain. A scFv with novel binding properties in
relation to mAb 3.1 was raised and characterized. The
capacity of such restricted mutations in altering antibody
functionality is discussed.
MATERIALS AND METHODS
Antigen production and hybridoma technique
The canine CSF-1R dimerization region (from the start
codon, nucleotides 1028 to 1306, accession XM_546306,
National Center for Biotechnology Information) was
cloned in pTriex1.1 (Millipore) and was expressed in
BL21 (DE3) Escherichia coli. The dimerization domain
was cleared from bacteria by sonication under denaturing
conditions (8 M urea). Purification was performed by
affinity chromatography with Ni-NTA resin (Qiagen). The
eluates were dialyzed against PBS after purification with a
stepwise reduction of urea.
Mice were immunized with the dimerization region of
CSF-1R every 28 days (at 50 µg/dose) using Freund’s adju-
vant in a total of four doses. The best cloneswere selected by
dot blots and ELISA. Immunizations and hybridoma pro-
ductionwere performed by theRegional Centre forApplied
Molecular Oncology, Masaryk Memorial Cancer Institute,
Brno, Czech Republic. Antibody isotype was determined
using a rapid lateral flow kit (IsoQuick, Sigma).
Immunofluorescence
For histological stains, tissue samples were fixed in
PBS + 4% paraformaldehyde. The samples were then
immersed in 20% and then 40% sucrose. Sections of 6 µm
were used. Sections were blocked in 10% goat serum and
were permeabilized by the addition of PBS + 0.2% Triton
X-100. Sections were incubated overnight at 4◦C with
hybridoma cell culture supernatants. Mouse anti-human
CD163 AM3K (TransGenic Inc.) and mouse anti-canine
CD11b (AbD Serotec) were used for comparison where
stated. Isotype control was mouse IgG1 (Abcam). Anti-
bodies were diluted in blocking buffer. Goat anti-mouse
Alexa 488 fluorescent secondary antibody (Invitrogen)
was used. Slides were mounted with VECTASHIELD
Mounting Media with 4´ ,6-Diamidine-2´-phenylindole
dihydrochloride (Vector Labs).
Real-time cell proliferation assay
To assess the functionality of the antibodies in blocking
macrophage survival in culture, real-time cell prolifera-
tion assays were performed. 3 × 104 canine bone marrow
macrophages were used. Cells were harvested as described
elsewhere [22]. Macrophages were grown in the presence
of rhCSF-1 (20 ng/ml, Invitrogen). Cells were placed on
an xCELLigence Real-Time Cell Analyzer (Roche) 96-well
plate in 100 µl of Rosewell Park Memorial Institute culture
medium. The plate was scanned to measure the initial
numbers of cells in each well, and then purified mAb 3.1
treatment was added. The small-molecule inhibitor of CSF-
1R, GW2580, was used as a control. Negative controls
received equivalent concentrations of murine serum IgG
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and antibodies were replaced during the experiment. Cells
were then maintained at 37◦C and 5% atmospheric CO2
for the duration of the experiment. Cell proliferation was
assessed every 15 min.
Inhibition of feline osteoclasts
To further analyze the inhibitory properties of mAb
3.1, feline osteoclasts were targeted with the antibody.
Feline bone marrow cells were differentiated for 10 days
in rhRANKL (30 ng/ml, R&D Systems) and rhCSF-1
(10 ng/ml, R&D Systems) in low adherence tissue culture
plates (Corning) (kindly provided by Seungmee Lee (Roslin
Institute)). Anti-CSF-1R mAb 3.1 hybridoma supernatant
or an irrelevant anti-CCR2 hybridoma supernatant was
added to the cells at 1/6 of the total culture volume. One
control well received no CSF-1 after the initial differentia-
tion of the cells. The culture medium and supplements were
renewed at 48 h. Cells were lysed on day 4 using 1 ml/well
of lysis buffer 15 (R&D Systems, Apoptosis Array Kit) for
30 min at 4◦C. The protein mixture was assessed by western
blotting. Membranes were probed with anti-pAkt (Ser 473)
and total Akt (both Cell Signaling). Antibodies were used
sequentially on the same membrane, after stripping the
nitrocellulose membrane using Restore PLUSWestern Blot
Stripping Buffer (Thermo Scientific). Secondary antibody
was swine anti-rabbit HRP-conjugated.
Flow cytometry
Canine blood was collected from animals from the Edin-
burgh Dog and Cat Home, euthanized for humane reasons.
Leucocytes were isolated from whole blood using Ficoll-
Paque, 1.077, (Sigma). Peripheral blood mononuclear cells
(PBMCs) were stained with purified mAb or hybridoma
supernatant (from 30 min to overnight, at 4◦C or room
temperature) or with scFv (40 min at 4◦C). An anti-swine
CSF-1R mAb was used as control (a kind gift from Lind-
sey Waddell, Roslin Institute). The anti-swine mAb had
no inhibitory capacity against the receptor. For mAb, a
goat anti-mouse secondary antibody was used, Alexa 488-
conjugated (Invitrogen). For scFv, an anti-His secondary
(Invitrogen) and a goat anti-mouse tertiary, Alexa 488-
conjugated (Invitrogen) were used. 7-AAD (eBioscience) or
Sytox blue (Invitrogen) were added 5 min before the analy-
sis for assessment of cell viability by flow cytometry. Cells
were analyzed on a FACScalibur flow cytometer (Becton
Dickinson). Data were analyzed using Summit 4.1 software
(Dako).
Immunoprecipitation
mAbs (21 µg) in sodium phosphate buffer (pH 7.0) were
bound to Protein G beads (GE Healthcare). Unbound
mAbs were removed by centrifuging and washing the
beads with sodium phosphate buffer. HEK293T cells were
transiently transfected to express the extracellular region
of CSF-1R [23]. One milliliter of the HEK supernatant
was incubated with the protein G + mAbs. The resin was
washed 5 × with sodium phosphate buffer. The resin was
incubated with 30 µl PBS + reducing sample buffer. This
was incubated at 95◦C for 5min andwas spun to precipitate
the resin. The supernatant was loaded into a 10% SDS-
PAGE gel. The western blot nitrocellulose membrane
was probed with mouse anti-His tag (Invitrogen) and
with goat anti-mouse, HRP-conjugated (Dako). N-linked
oligosaccharides were removed from the extracellular
region ofCSF-1Rusing PNGase F (Promega). The purified
extracellular region (50 µg in 12 µl of 0.5 M sodium
phosphate buffer, pH 7.5) was mixed with 1 µl SDS (5%)
and 1 µl DL-Dithiothreitol (DTT) (1 M). The sample was
denatured at 95◦C for 5 min and was cooled at room
temperature for 5 min. Sodium phosphate buffer, NP-40
(10%) and PNGase F (2 µl each) were added to the mixture.
This was incubated at 37◦C for 2 h. Samples were resolved
in a 10% SDS-PAGE gel and were analyzed by Ponceau
S staining of the proteins transferred to a nitrocellulose
membrane.
Site-directed CDR mutagenesis
The cloning of the antibody variable region was conducted
according to [24]. CDR mutagenesis of the sequence cor-
responding to five amino acids was performed by PCR
using specific oligonucleotides. Mutagenesis primers were
designed to bind to the regions around CDR2 of the Vh
chain (Fig. 1). Within the CDRs, the mutagenesis primers
contained areas of degenerate sequences that coded for all
possible amino acids and one stop codon (amber codon,
TAG), using the degenerate sequence ‘NNK’. The primers
contained restriction sites for insertion into the phagemid
pSEX81 (Progen). This phagemid was ligated with the
normal VL chain frommAb 3.1 and the mutated Vh chain.
Phage display—phage library biopanning
For the identification of the most suitable clones from the
phage libraries, thesewere screened against the extracellular
region of the canine CSF-1R, expressed by HEK293T cells.
Methods were according to [25]. Immunotubes (Greiner)
were coated overnight at 4◦C with 0.5 ml of PBS con-
taining 25 µg (rounds 1 and 2 of panning) or 12.5 µg
(further rounds) of the CSF-1R protein. The tube was
then blocked with 2% milk. Bound phage was eluted with
trypsin (10 mg/ml, Gibco). ELISA for testing the phage is
described below. Bovine serum albumin (BSA) was used as
a control target protein in separate wells. Mouse anti-M13
antibody (1:1 000, GEHealthcare) was used to detect phage
particles bound to the plate. Rabbit anti-mouse IgG, HRP-
conjugated (1:2 000, Dako), was used as the tertiary anti-
body.HRP activity was detected using TMB substrate (Mil-
lipore). Negative control wells received only the secondary
and tertiary antibodies.
Expressing the scFv independently from the phage
The variable regions of the monoclonal antibodies iden-
tified from the mutated library were amplified by PCR
and were ligated into the pOPE101 plasmid (Progen).
These clones were characterized by standard Sanger
sequencing (Dundee Sequencing). For scFv production, the
bacterial culture was induced with 500 µM Isopropyl
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Figure 1. PCR strategy for the mutagenesis of mAb 3.1. The arrows represent primers. The PCR product sizes are indicated in base pairs (bp). The figure
is not to scale. The boxes within primer II show the points where mutations were inserted in each region. Several PCR steps were required for the full
assembly of each of the variable regions, shown as PCR 1, PCR 2 and PCR 3. The lines in PCR 2 indicate the products from PCR 1.
at 37◦C. The soluble protein fraction was removed by
bacterial lysis using a mild buffer (200 mM Tris–HCl; 20%
sucrose; 1 mM EDTA, pH 8.0). The insoluble remaining
pellet was then resuspended (in 10% of the initial culture
volume) in a denaturing buffer (50 mM Tris–HCl, 50 mM
NaCl, 1 mM EDTA, 8 M urea, pH 8.0; 10 mM DTT
was added immediately before using the buffer). The
pellet was solubilized in this buffer overnight at 4◦C.
The scFv were then refolded by dialysis with a stepwise
reduction in the concentration of urea in 1.5 l of the
same buffer. After dialysis, the soluble scFv was affinity
purified with a Ni-NTA resin (Qiagen). The refolded scFv
was dialyzed thrice against PBS to remove imidazole.
Protein concentration was measured with a NanoDrop
spectrophotometer (Thermo Scientific) at 280 nm.
Endpoint proliferation assay
For the assessment of scFv inhibitory activity, an endpoint
proliferation assay was used. Cells were treated with either
a scFv, the parental mAb 3.1 (at the same concentration) or
PBS, as the vehicle control for the scFv. 3× 104 canine bone
marrow macrophages or NIH/3T3 were plated in 100 µl
of DMEM medium (Gibco) in individual wells of black
opaque 96-well plates (Greiner). The purified scFv, mAb
3.1 and/or rhCSF-1 (100 ng/ml, Invitrogen) were added to
the culture at the same time as the cells. After 48 h, viable
cells were quantified using CellTiter-Glo, Promega.
ELISA for scFv specificity
An ELISA assay was used to compare antibody specificity
before and after mutagenesis. MaxiSorp 96-well plates
(Nunc) were coated with 400 ng/well of either canine
recombinant CSF-1R extracellular region or BSA in 50 µl
of PBS. After blocking, purified mAb 3.1 (12 or 30 µg) or
scFv were added to the wells. Secondary antibody (for the
mAb) was a rabbit anti-mouse HRP (1:2 000, Dako). The
scFvwas detectedwith an anti-c-Myc tag,HRP-conjugated
(1:10 000, Bethyl Laboratories). Negative controls received
only the secondary anti-mouse or anti-cMyc antibodies.
The reaction was developed with TMB Ultra (Fisher).
Absorbance was read at 450 nm (Victor3, Perkin Elmer).
Inhibition of CSF-1 binding
The ability of themutated antibody to blockCSF-1 binding
was tested. A swine CSF-1-Fc fusion was used, coupled
to Alexa Fluor 648 (a kind gift from Anna Raper, The
Roslin Institute) [26–28]. Canine peripheral blood mono-
cytes or bone marrow–derived macrophages (50 000 cells)
were blocked with either 40 or 10 µg of scFv for 1 h at
37◦C. Next, CSF-1-Fc was added to the cells at the same
conditions. Finally, cells were washed with PBS and were
read in a flow cytometer. Controls consisted of either cells
stained with CSF-1-Fc in the presence of the scFv elution
buffer or of cells stained with an anti-canine MHC class II
antibody after addition of scFv (40 µg) instead of the CSF-
1-Fc stain (Bio-RadMCA1044F, FITC-coupled, 1:50). The
experiment was performed three times independently.
Statistical analyses
The real-time proliferation assays were assessed using
repeated-measures two-way ANOVA with either Fisher or
Holm–Sidak post hoc tests. The proliferation assay using
purified scFv was analyzed using one-way ANOVA. For
all tests, P < 0.05. Assumption tests were performed on
Minitab 16 (Minitab Inc.). Statistical tests and graphs were
made on GraphPad Prism 5 (GraphPad Inc.).
RESULTS
Hybridoma clones
Several clones were obtained by hybridoma fusion and
mAb 3.1 was selected, among others, by dot blot and
ELISA assays (not shown) and was therefore analyzed for
its binding characteristics and binding properties. mAb 3.1
was of the IgG1 isotype.
mAb 3.1 could stain macrophages in fixed canine tissues
A range of canine tissues was stained with the hybridoma
supernatant of mAb 3.1 by immunofluorescence. mAb 3.1
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and spleen. Commercial control antibodies against CD163
and CD11b showed similar staining patterns to mAb 3.1
(Fig. 2A, B, E). In the duodenum, mAb 3.1+ cells were
present around the duodenal glands and infiltrating the
villi, as were CD163+ cells (Fig. 2C, D). In the spleen, mAb
3.1+ cells surrounded the white pulp, as did CD11b+ cells
(Fig. 2F). In the lymph node, mAb 3.1+ cells were mostly
seen in the medullary cords and the paracortical areas but
also close to the subcapsular space and the trabeculae (not
shown).
mAb 3.1 had an inhibitory effect on canine primary
macrophage cultures
The capacity of the anti-CSF1-1R mAb 3.1 to block the
proliferation of canine macrophages was analyzed with
a real-time proliferation assay. The proliferation curve of
mAb 3.1-treated macrophages was different from the iso-
type control at 1.25 µg/well (Holm–Sidak post hoc test)
and showed a trend of significant activity at 3.75 and
7.5 µg/well (differences were only significant with a Fisher
post hoc test). GW2580, a small-molecule inhibitor of CSF-
1R,was used as an inhibition control andwas able to reduce
macrophage survival at 20 µM in relation to its DMSO
vehicle control (Fig. 3A).
mAb 3.1 inhibited osteoclast survival
Osteoclasts have a distinct morphology, forming a tight
‘tiled’ structure in cell culture. Therefore, apoptosis is easy
to identify in culture, as this tiled pattern is then broken
[29]. The feline and the canine CSF-1R have 82% homology
when only the extracellular region is considered—this is
the region targeted by mAb 3.1. When mAb 3.1 was used
on feline osteoclasts, it induced phenotypical alterations
that indicate cellular contraction and membrane blebbing.
The use of a control antibody (anti-CCR2 mAb) or the
removal of CSF-1 after the cells that had differentiated had
no effect on cellular morphology and, in these cases, the
cells maintained a ‘tiled’ pattern (Fig. 3B). The CSF-1R
signaling pathways were evaluated in osteoclasts by western
blotting. While total Akt was stable between treatments,
pAkt was reduced in mAb 3.1-treated cells (Fig. 3C).
mAb 3.1 could not recognize some glycoforms of CSF-1R
Despite the aforementioned properties of mAb 3.1, it could
not stain peripheral blood mononuclear cells (PBMCs)
from dogs, regardless of staining time (from 30 min to
overnight) or whether purified antibodies or hybridoma
supernatants were used. The positive control, an anti-
swine CSF-1R, bound almost exclusively to canine mono-
cytes, showing little background staining of lymphocytes
(Fig. 4A).
To determine the reasons of such unexpected results,
mAb 3.1 was used in an immunoprecipitation assay with a
recombinant CSF-1R extracellular region. mAb 3.1 recov-
ered proteins with the correct molecular weight of CSF-1R,
but it is only bound to a narrow range of the glycoforms of
CSF-1R (Fig. 4B).
Figure 2. mAb 3.1 stained putative macrophages in several canine tissues.
(A)Duodenal villi and (B) duodenal glands stainedwith anti-CD163 (1:75,
TransGenic Inc.), used as a positive control. (C) Duodenum stained with
hybridoma supernatant containing mAb 3.1 (60 µg/ml) showing villi in
profile. (D) mAb 3.1 stain, showing duodenal glands. (E) CD11b (1:10,
AbD Serotec) stained spleen, used as a positive control. (F) Spleen stained
with hybridoma supernatant containing mAb 3.1. (G) Isotype control
IgG1k for the duodenal stain (80 µg/ml, Abcam). (H) Secondary antibody
control for the spleen stain (1:300 goat anti-mouse, Invitrogen). Notice the
similar distribution of cells stained with the controls (A, B, E) and mAb
3.1 (C, D, F). Secondary antibody was goat anti-mouse Alexa 488 (1:300,
Invitrogen). The nuclear stain is in blue (DAPI). The white arrows indicate
duodenal glands (A–D); the yellow arrows indicate the central arteriole (E,
F). The red arrows indicate the limits of the white pulp. ‘20 ×’ and ‘40 ×’
indicate the magnification used to acquire the images. The yellow puncta
in the secondary control stain of the spleen are believed to be lipofuscin
granules due to their fluorescence patterns [50].
Selection of CDR2 mutants yielded hydrophilic and
glycine-rich scFv
The CDR2 of mAb 3.1 was mutated by PCR, and nine
phage display–selected mutated scFv were sequenced
and compared to the original mAb 3.1, from which the
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Figure 3. mAb 3.1 inhibited cellular proliferation. (A) Effect of mAb 3.1 in proliferation assay of canine BMDM. Cells (in 100 µl medium) were grown
in rhCSF-1 (20 ng/ml, Invitrogen) and treated with the purified mAb (at 1.2, 3.75 or 7.5 µg) or GW2580 (20 µM), as a control. The negative controls
received equivalent concentrations of mouse serum IgG antibody (Sigma) or DMSO (vehicle control for GW2580). Data was collected every 15 min.
Treatments were added at 17 h. Data were also normalized at that point. The abrupt drops in the graphs indicate when the plate was removed from the
xCelligence equipment for change of medium/treatment. Results are shown as means of four wells (two wells at 7.5 µg) ± SD for each time point. Results
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Figure 4. mAb 3.1 did not stain canine PBMCs. (A) Live cells stained with mAb 3.1 (10 µg/ml) or mouse anti-swine CSF-1R (25 µg/ml, Lindsey Waddell,
Roslin Institute). Cell viability was assessed using Sytox blue (Invitrogen). Fluorescence intensity is shown on the x-axis and cell granularity on the y-
axis. Secondary antibody was goat anti-mouse Alexa 488 (1:800, Invitrogen). (B) Immunoprecipitation of CSF-1R with mAb 3.1. Purified murine mAb
3.1 or isotype control (21 µg) were coupled to protein G beads (75 µl, GE Healthcare). Unbound antibodies were removed by washing. Medium from
transiently transfected HEK293T cells expressing CSF-1R extracellular region was added to the beads and incubated overnight at 4◦C. Unbound proteins
were removed by washing. The resin was incubated with reducing sample buffer at 95◦C for 5 min. The mixture was centrifuged, and the supernatant
was resolved by SDS-PAGE. His-tagged proteins were identified by western blotting (anti-His at 1:500, Invitrogen). Secondary antibody was anti-mouse,
HRP-conjugated (Dako, 1:1 000). (C) The recombinant extracellular region of CSF-1R was glycosylated, which induced a broad band pattern on the
SDS-PAGE. This is evidence that mAb3.1 bound only to selected glycoforms. The recombinant protein was digested with PNGase F and the resulting
difference in molecular size was evaluated by SDS-PAGE separation of the deglycosylated and control CSF-1R.
The selected mutants coincided in the selection of proline
and glycine residues and increased solubility. Four of the
nine sequenced scFv had increased charge (Table 1).
A mutated version of mAb 3.1—a scFv—showed novel
functions
The biological activity of the mutated version of mAb 3.1, a
scFv, against bonemarrow-derivedmacrophages (BMDM)
was tested in a proliferation assay. The murine fibroblast
NIH/3T3 cell line was used as a control to assess if the
effect of the scFv was indiscriminate or dependent on
any bacterial contaminant remaining from the purification
process. Whereas mAb 3.1 marginally reduced BMDM
proliferation at the concentration used, the scFv reduced
BMDM survival even when compared to mAb 3.1. Also,
the scFv did not impair NIH/3T3 survival (Fig. 5A).
In an ELISA assay, the scFv demonstrated reduced
binding to two control proteins compared to the parental
mAb, BSA and soybean trypsin inhibitor (Fig. 5M).
The scFv was tested by flow cytometry for binding to
canine peripheral blood mononuclear cells (PBMC). The
scFv bound exclusively to live canine monocytes, but not
to lymphocytes or granulocytes. Staining with the scFv
was greatly reduced if the cells were previously fixed in
paraformaldehyde (Fig. 5C).
scFv inhibited CSF-1 association to canine phagocytes
Stable CSF-1 interaction with its receptor depends on CSF-
1R dimerization, which ‘locks’ the ligand within the dimer,
while the complex is directed toward internalization [21].
mAb 3.1 was generated against the CSF-1R dimerization
region; so, it was tested whether its mutated form, the
scFv, could inhibit CSF-1 binding by blocking receptor
dimerization. Cells were stained with a fluorescent CSF-
1 following scFv blockade. The scFv could inhibit CSF-1
binding to canine PBMC and BMDM in a dose-dependent
manner. The scFv did not affect other receptors, as it could
statistical differences appear. (B) mAb 3.1 induced apoptosis of feline osteoclasts. Bright field images of feline osteoclasts grown with rhCSF-1 (10 ng/ml,
R&D Systems) and rhRANKL (30 ng/ml, R&D Systems) treated with hybridoma culture supernatant containing mAb 3.1 (1/6 of medium volume in
osteoclast culture) for 4 days and comparisons with anti-CCR2 hybridoma culture supernatant (similar dose), untreated and no CSF-1 controls. Cellular
membranes were manually outlined to highlight the differences between the groups. Pictures are representative of two wells for the negative controls
and mAb 3.1 treated cells, and of a single well for the anti-CCR2 treated cells. (C) mAb 3.1 reduced pAkt in feline osteoclasts. Proteins from the lysed
osteoclasts from (B) (20 µg/well) were resolved by SDS-PAGE and transferred onto a nitrocellulose membrane. The same membrane was probed with
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Figure 5. The scFv had different binding properties compared to the parental mAb 3.1. (A) Canine BMDM were grown with rhCSF-1 (20 ng/ml,
Invitrogen) and treated with 10 µl of scFv or the parental mAb 3.1 (both at 0.3 mg/ml). PBS was used as vehicle control for the scFv. The murine
fibroblast NIH/3T3 cell line was used as a control to assess if bacterial products remaining from the purification had toxic effects. These cells received the
same treatments as the BMDM (but no CSF-1). Cells were incubated with the treatments for 60 h. The treatment had no effect on NIH cells. Proliferation
results as measured by luciferase activity (CellTiter-Glo, Promega). Results are the means of at least eight wells. Data representative of three independent
experiments. Data analyzed by ANOVA. Statistically, significant differences are indicated by differing letters above each group. (B) The refolded scFv
displayed improved binding characteristics when compared to the parent mAb 3.1. The purified and refolded scFv and the murine mAb 3.1 were tested by
ELISA in wells coated either with the canine extracellular region of CSF-1R, BSA or soybean trypsin inhibitor (Sigma) (all at 400 ng/well in 50 µl of PBS).
scFv had reduced binding to the control proteins when compared tomAb 3.1. scFv was detected with an anti-c-Myc tag, HRP-conjugated (1:10 000, Bethyl
Laboratories). mAb 3.1 was detected with an anti-mouse Ig HRP-conjugated antibody (1:2 000, Dako). Negative controls received only the secondary
anti-mouse or anti-cMyc antibodies. Result representative of three independent assays. (C) Refolded scFv bound to canine monocytes. Fixed (1% PFA,
left) or live (right) canine peripheral blood mononuclear cells were stained with 50 µl of urea-refolded scFv for 40 min on ice. After washing cells, bound
scFv was detected using mouse anti-His tag (1:700, Invitrogen) and goat anti-mouse, Alexa 488-conjugated (1:800, Invitrogen). Cell viability was assessed
with 7-AAD (eBioscience). In this graph, the cellular populations with an SSC-H above ∼128 are granulocytes; between ∼64 and 128 are monocytes;
under ∼64 are lymphocytes.
not interfere with the staining of cells with an anti-canine
MHC class II antibody (Fig. 6).
DISCUSSION
The tumor microenvironment and the infiltrated immune
cells are believed to be potential targets in cancer. The
immune components of the tumor bulk are not only toler-
ant to the cancer cells but can also in fact promote their
growth [30, 31]. This work demonstrates the characteri-
zation of a monoclonal antibody, mAb 3.1, with poten-
tial to inhibit macrophage survival and proliferation by
blocking the CSF-1R. These antibodies were created with
the intent of affecting the population of tumor-associated
macrophages (TAMs), which majorly exhibit pro-tumoral
activity [32].
mAb 3.1 could identify cells within normal fixed canine
tissues that are compatible with the spatial distribution
of macrophages [33]. In the spleen, there is a population
of CSF-1Rbright+ cells surrounding the lymphoid follicles of
the spleen [7], which could correspond to the cells stained
by mAb 3.1. When the mAb was used to stain lymph
nodes, the cells of the medullary cords were preferentially
marked, with increased intensity compared to other areas
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Figure 6. The scFv reduced binding of CSF-1 to canine BMDM and PBMC. (A) Cells were blocked with two concentrations of scFv for 1 h (10 or 40 µg),
followed by staining with a fluorescent swine recombinant CSF-1-Fc for 1 h. Increasing concentrations of the antibody fragments reduced CSF-1 binding
to the cells. (B) The scFv did not interfere with the staining of these cells with a commercial anti-MHC class II antibody. Results shown are representative
of the assays conducted with BMDM.
highly express the CSF-1R [33]. mAb 3.1 stained cells in
the same tissue compartments as other markers such as
CD163 and CD11b, which confirms that those cells are
likely macrophages [34–36].
mAb 3.1 was raised using the dimerization domain of
CSF-1R as an antigen. Blocking receptor dimerization has
been shown to be an effective means to impede recep-
tor function [37]. Probably through this mechanism, mAb
3.1 could inhibit BMDM proliferation. Although mAb
3.1 seemed consistent in reducing cellular proliferation,
only high concentrations of the mAb were able to affect
macrophage replication (∼12.5 µg/ml); published CSF-1R-
blocking antibodies are effective in the range of 0.1–1 µg/ml
[8]. This indicates that the interaction of mAb 3.1 with
CSF-1R is weak.
Nevertheless, the effects of mAb 3.1 on cell survival were
confirmed using feline osteoclasts. The inhibition assay
with osteoclasts was performed because these cells have a
distinct morphology, forming a tight ‘tiled’ structure.When
cells undergo apoptosis, they naturally retract. Detecting
this occurrence on osteoclasts is simple because of the char-
acteristic arrangement of the cells in culture [29]. Apoptosis
was induced using mAb 3.1 but not a control anti-CCR2
monoclonal. When the molecular pathways were analyzed,
it could be seen that only mAb 3.1 induced a reduction
in the phosphorylation of Akt, which is important for cell
survival mediated through CSF-1R [38].
Despite the aforementioned properties of mAb 3.1, it
could not stain fresh peripheral blood monocytes from
dogs. The reduced capacity to bind to the native CSF-1R
may be due to differences in conformation between the
antigen used to create mAb 3.1 and the native protein.
mAb 3.1 was produced by immunizing mice with a small
recombinant protein (dimerization region of the receptor)
produced in bacteria. The different protein conformation
due to bacterial origin could explain the binding of mAb
3.1 to fixed tissues but not to the native soluble protein
expressed on monocytes. Also, in immunoprecipitation,
mAb 3.1 bound only to a narrow range of the glycoforms of
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Table 1. Mutated CDR2 regions of phage display-selected scFv.
The original CDR2 from mAb 3.1 is shaded in gray. The under-
lined glycine (G) was not mutated to preserve protein conforma-
tion, as this residue is important in loop formation in the CDRs.
GRAVY, grand average of hydropathicity. Parameters calculated
















of the antigen used for producing this antibody influenced
its binding properties.
To improve the characteristics of this antibody, a semi-
synthetic library was produced by mutating the variable
region of mAb 3.1. Five amino acids from the CDR2 of
the Vh chain were mutated by PCR. Such a reduced span
in the mutations was an attempt to improve an existing
antibody without greatly altering its fundamental capaci-
ties, since mAb 3.1 had shown some capacity to bind to
CSF-1R. Evidently, for antibodies, even small alterations
of the CDRs are sufficient to alter the binding specificity
and affinity [39]. Vh CDR2 was selected for mutation for
two reasons. Firstly, Vh CDR3 largely determines antibody
specificity [40]; since mAb3.1 could recognize the desired
target, mutations were not performed in this region to avoid
loss of function. Also, Vh CDR2 has considerable sequence
tolerance, so that amino acids can be largely altered with no
influence on loop formation. This hypervariable antibody
region follows only Vh CDR3 in this aspect [41].
Nevertheless, Vh CDR2 shows some constraints regard-
ing ‘viable’ primary sequences. To maintain conformation,
amino acids in this region must form β-hairpin structures.
As determined by Cheng and colleagues, ‘the loop residues
in the CDR-H2 have moderate preferences for hydrophilic
or turn (Gly and Pro) amino acid types’ [42]. Indeed, the
nine sequenced mutated CDR2 coincided in the preva-
lence of these amino acids. It is possible that increased
solubility was important for the functional gains seen in
mutated scFv. In naïve antibody repertoires, Tyr, Ser and
Gly combine to confer specificity. This seemed to be the
case for the original mAb3.1 Vh CDR2 region, in which
5/6 amino acids in the mutated region were Ser or Gly
[43]. However, in activated antibody repertoires, Tyr is often
associatedwith specificity, but it was not enriched following
scFv selection in the present study [44]. Increased anti-
body function following mutations may have been gained
via increased solubility. Short-chain hydrophilic residues
(includingGly) are enriched in antibody paratopes, and this
was unanimously found in the mutated scFv [44]. The lack
of Tyr and Ser mutants is an indication of the shortfalls
of the parsimonious mutations created in this project. The
localization of themutations seems to have been selected for
residues that are critical in maintaining antibody structure,
perhaps hampering the appearance of more specific clones.
The mutant library was screened against a recombinant
version of the extracellular region of the canine CSF-1R
produced in mammalian cells and whose conformation
was similar to that of the natural protein. The library was
also negatively selected for BSA binding [23]. Thus, it was
expected that new clones derived from mAb 3.1 would
arise that would be able to bind to the native form of the
receptor, and not only to the original bacterially derived
immunogen.
The scFv originated from themutated library showed sig-
nificant changes in binding compared to the original mAb.
The scFv preferentially bound to CSF-1R and had reduced
cross-reactivity with control proteins when compared to the
parental mAb. This indicates that the mutation of the CDR
2 of the Vh chain of mAb 3.1 was a step toward perfecting
the binding properties of the mAb.
The addition of the scFv tomacrophage cultures affected
BMDM proliferation to a greater extent than the parental
mAb 3.1. Confounding factors include contaminant E.
coli bacterial proteins derived from scFv purification, since
affinity chromatography did not completely remove non-
specific proteins (not shown). However, the scFv (or the
impurities) had no effect over the proliferation of a murine
fibroblast cell line (NIH/3T3) that was used as a control.
Both macrophages and NIH/3T3 cells express at least some
pathogen-associated molecular pattern receptors, such as
Toll-like receptors, which could recognize residues ofE. coli
and negatively affect cellular proliferation. Since NIH/3T3
proliferation was unaffected by the scFv solution, there is
an indication that bacterial contaminants were not an issue.
Nevertheless, macrophages are more sensitive to some bac-
terial products than the fibroblast cell line and could have
been more negatively affected by the presence of residues
[45, 46].
Confirming that the binding properties of the antibody
were greatly changed by mutation of CDR 2, the scFv
were shown to specifically bind to unfixed monocytes
from canine peripheral blood. This is in contrast with
the parental mAb 3.1, which was useful for staining fixed
tissues but could not identify cells from fresh blood. This
confirms the specificity of the scFv to CSF-1R, since other
peripheral blood cells do not express this receptor [47]. The
scFv was also effective in reducing the attachment of CSF-
1 to canine BMDM or PBMC. Upon ligand interaction,
CSF-1R dimerizes, stabilizing the contact with CSF-1. The
scFv may have hampered CSF-1 attachment by blocking
the dimerization of the receptor.
Overall, these results confirm that it is possible to
change and improve antibody specificity and binding
through the construction and selection of small libraries
of mutant antibodies created with only selected CDR
alterations. Therefore, the present study was novel in
the selection of the mutated region and in its reduced
size [48], while still showing antibody improvements. A
shortfall of the method was in not selecting for amino






/abt/article/3/3/193/5891586 by guest on 10 M
ay 2021
Beirão et al. 11
findings enable further enhancements of the anti-CSF-
1R antibodies through further mutations of the already
improved antibodies. Subsequent improvements of the
mutated scFv could be achieved by blocking the library
with proteins of similar structure to CSF-1R, such as c-Kit
and the platelet-derived growth factor receptor (PDGFR)
[49]. In this manner, antibodies that undesirably recognized
these related proteins would be depleted. Still, the scFv
demonstrated here already shows promise for future animal
trials.
This article was assessed by reviewers during the unique
time of the coronavirus disease (COVID)-19 pandemic.
Further experiments were then deemed necessary, but the
authors were unable to proceed with them due to the clo-
sure of the research facility where the work was carried
out. These experiments were for SPR comparison of mAb
3.1 and the scFv and a demonstration of colocalization
of CD163 with the staining from mAb 3.1. The authors
acknowledge the need for these experiments, and this shall
be the subject of our future work.
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